A Bayesian Zero-Inflated Binomial Regression and Its Application in Dose-Finding Study
Abstract
In early phase clinical trial, finding maximum-tolerated dose (MTD) is a very important goal. Many researches show that finding a correct MTD can improve drug efficacy and safety significantly. Usually, dose-finding trials start from very low doses, so in many cases, more than 50% patients or cohorts do not have dose-limiting toxicity (DLT), but DLT may occur suddenly and increase fast along with just two or three doses. Although some fantastic models were built to find MTD, little consideration was given to those 0 DLTs and the jump of DLTs. We developed a Bayesian zero-inflated binomial regression for dose-finding study based on Hall (2000), which analyses dose-finding data from two aspects: 1) observation of only zeros, 2) number of DLTs based on binomial distribution, so it can help us analyse if the cohorts without DLT have potential possibility to have DLT and fit the jump of DLTs.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 6
- FWCI
- 0.00
- Field percentile
- 18th percentile
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Costing ‘the’ MTD
David C. Norris·bioRxiv·Aug 22, 2017
- BayesCurveFit: Enhancing Curve Fitting for Early-Stage Compound Screening Using Bayesian Inference
- Robust and Efficient Assessment of Potency (REAP): A Quantitative Tool for Dose-response Curve Estimation
- Predicting drug safety and communicating risk: benefits of a Bayesian approach
S. E. Lazic, N. Edmunds, C. E. Pollard·bioRxiv·Nov 1, 2017
- A Bayesian phase 2 model based adaptive design to optimise antivenom dosing: application to a dose-finding trial for a novel Russell's viper antivenom in Myanmar
J. A. Watson, T. Lamb, … E. A. Ashley·bioRxiv·Feb 6, 2020
- Biostatistics and its impact on hazard characterization using in vitro developmental neurotoxicity assays
Hagen Eike Keßel, Stefan Masjosthusmann, … Ellen Fritsche·ALTEXPeer-reviewed·Jan 1, 2023